Alliancebernstein L.P. boosted its position in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) by 50.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 936,790 shares of the biopharmaceutical company’s stock after acquiring an additional 312,988 shares during the quarter. Alliancebernstein L.P. owned 3.58% of Loxo Oncology worth $75,121,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LOXO. Teachers Advisors LLC raised its position in Loxo Oncology by 4.3% during the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after acquiring an additional 905 shares in the last quarter. Nationwide Fund Advisors raised its position in Loxo Oncology by 31.9% during the first quarter. Nationwide Fund Advisors now owns 27,434 shares of the biopharmaceutical company’s stock worth $1,154,000 after acquiring an additional 6,632 shares in the last quarter. Wells Fargo & Company MN raised its position in Loxo Oncology by 33.3% during the first quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock worth $653,000 after acquiring an additional 3,875 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in Loxo Oncology by 92.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 9,200 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Loxo Oncology by 41.8% during the first quarter. Bank of New York Mellon Corp now owns 102,442 shares of the biopharmaceutical company’s stock worth $4,310,000 after acquiring an additional 30,210 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “Alliancebernstein L.P. Has $75.12 Million Holdings in Loxo Oncology, Inc. (LOXO)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/13/alliancebernstein-l-p-has-75-12-million-holdings-in-loxo-oncology-inc-loxo.html.

LOXO has been the topic of several analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $91.00 price target on shares of Loxo Oncology in a research report on Monday, June 19th. Stifel Nicolaus upped their price target on shares of Loxo Oncology from $52.00 to $71.00 and gave the stock a “buy” rating in a research report on Monday, June 5th. Citigroup Inc. raised shares of Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 price target on the stock in a research report on Monday, June 5th. BTIG Research reaffirmed a “buy” rating and set a $75.00 price target on shares of Loxo Oncology in a research report on Tuesday, June 6th. Finally, JMP Securities lowered shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $83.12 to $17.14 in a research report on Tuesday, August 29th. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Loxo Oncology has an average rating of “Buy” and a consensus price target of $70.73.

In other Loxo Oncology news, CEO Joshua H. Bilenker sold 7,500 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $73.73, for a total transaction of $552,975.00. Following the transaction, the chief executive officer now directly owns 196,207 shares in the company, valued at approximately $14,466,342.11. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joshua H. Bilenker sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $73.56, for a total value of $1,103,400.00. Following the transaction, the chief executive officer now owns 196,207 shares in the company, valued at $14,432,986.92. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,073 shares of company stock worth $3,397,662. Company insiders own 27.80% of the company’s stock.

Loxo Oncology, Inc. (NASDAQ LOXO) opened at 75.11 on Wednesday. The firm has a 50 day moving average of $74.89 and a 200 day moving average of $60.19. The firm’s market capitalization is $2.24 billion. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $84.46.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.15). During the same quarter last year, the company posted ($0.77) earnings per share. On average, analysts forecast that Loxo Oncology, Inc. will post ($4.54) EPS for the current fiscal year.

Loxo Oncology Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.